SCYNEXIS Announces Launch of Initial Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Drug discovery and development company SCYNEXIS, Inc., today announced that it plans to commence a road show on March 24, 2014 for the proposed initial public offering of shares of its common stock. SCYNEXIS has filed a registration statement with the Securities and Exchange Commission to offer 4,230,800 shares of its common stock to the public. The initial public offering price is currently expected to be between $12.00 and $14.00 per share. The underwriters have an option to purchase an additional 634,620 shares of common stock at the initial public offering price less the underwriting discount, within 30 days from the date of the offering.
An application has been made to list the common stock of SCYNEXIS on the NASDAQ Global Market under the symbol "SCYX."
RBC Capital Markets and Canaccord Genuity are serving as joint bookrunning managers. In addition, JMP Securities is participating as lead manager in the offering. The offering of SCYNEXIS common stock will be made only by means of a prospectus. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When available, a copy of the preliminary prospectus relating to the proposed initial public offering may be obtained on the SEC EDGAR Filings Website: http://www.sec.gov/edgar/searchedgar/companysearch.html. Until then, you may obtain more information by contacting RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, telephone (877) 822-4089 or Canaccord Genuity Inc., Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, telephone (617) 371-3900.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services in primarily in the field of animal health. www.scynexis.com
Company
SCYNEXIS
Amanda Mancuso, 919-544-8663
Chief
of Staff
amanda.mancuso@scynexis.com
or
Media
Relations
MacDougall Biomedical Communications
Cory
Tromblee, 781-235-3060
ctromblee@macbiocom.com
Source: SCYNEXIS
Released March 24, 2014